This document relates to bioengineering and involves bioengineered thymus organoids and related humanized animal models. The thymus organoids and animal models have various commercial and clinical uses, including generating humanized antibodies, making antigen-specific human T cells, inducing transplantation tolerance, rejuvenating thymus functions, and modeling human diseases.

The invention relates to a three-dimensional in vitro alveolar lung model comprising essentially the four cells types as follows: alveolar type II epithelial cells able to secrete (lung laying) surfactant, endothelial cells which forms the inner lining of capillaries providing a permeable barrier, dendritic-like cells, such as non-differentiated THP-1, linking innate and adaptive immunity and macrophage-like cells, able to participate to defense mechanisms by ingesting foreign materials by phagocytosis. The invention also relates to a process for preparing said model, and its use for assessing the irritation potential or toxicity of inhalable products such as particles or molecules on the alveolar barrier of lungs, and also for determining and/or predicting the sensitizing effects of inhalable products such as particles or molecules on the alveolar barrier of lungs.

Provided are engineered meat products formed as a plurality of at least partially fused layers, wherein each layer comprises at least partially fused multicellular bodies comprising non-human myocytes and wherein the engineered meat is comestible. Also provided are multicellular bodies comprising a plurality of non-human myocytes that are adhered and/or cohered to one another; wherein the multicellular bodies are arranged adjacently on a nutrient-permeable support substrate and maintained in culture to allow the multicellular bodies to at least partially fuse to form a substantially planar layer for use in formation of engineered meat. Further described herein are methods of forming engineered meat utilizing said layers.

The present invention discloses, in one embodiment, a method of using human induced pluripotent stem cells to generate three-dimensional human organ tissue for therapeutic drug toxicity and discovery⋅. In one embodiment, a high throughput microtiter plate is loaded with both wild type and Rett disease 3D spheroids and exposed to a drug library, and activity is measured and analyzed for disease rescue to wild type cell behavior.

The invention relates to methods for the isolation of non-haematopoietic tissue-resident lymphocytes, particularly γδ T cells. Such γδ T cells include non-Vδ2 cells, e.g. Vδ1, Vδ3 and Vδ5 cells and such non-haematopoietic tissues include skin and gut. It will be appreciated that such isolated non-haematopoietic tissue-resident lymphocytes find great utility in adoptive T cell therapies, chimeric receptor therapies and the like. Also provided are methods for expanding isolated tissue-resident lymphocytes, particularly methods for isolating and expanding γδ T cells. The present invention also relates to both individual cells and populations of cells produced by the methods described herein.

The present invention provides a kidney production method including a step of tissue-specifically removing a metanephric mesenchyme of a metanephros of a non-human animal; a step of transplanting, into the metanephros, a kidney precursor cell derived from a non-human animal which is allogeneic or xenogeneic to the non-human animal; and a step of advancing development of the metanephros, which is a step in which the transplanted kidney precursor cell is differentiated and matured to form a part of the kidney.

Disclosed herein are compositions and methods to decellularize an isolated organ or portion thereof. Also disclosed herein are compositions and methods for treatment of disease utilizing a decellularized or recellularized organ. Also disclosed herein are methods of improving decellularization and/or recellularization of an isolated organ or portion thereof.

A method of producing a 3D tissue composite, comprising: a preparation step in which a multiple number of sheet-shaped first structures containing first cells are prepared, wherein at least one of the multiple number of first structures holds a second structure containing second cells; a stacking step in which the multiple number of first structures are stacked to form a 3D composite; and a culturing step in which the 3D composite is cultured to form a 3D tissue composite containing first tissues formed from the first cells and second tissues formed from the second cells.

The present invention provides a valve material having synergistic anti-coagulation and anti-calcification functions and a preparation method therefor. The preparation method comprises the following steps: performing glutaraldehyde cross-linking treatment on an animal-derived biological valve material; immersing the treated valve material in a blocking solution containing an amine compound for 0.5-6 h, thereby blocking the remaining aldehyde groups after glutaraldehyde cross-linking; then placing the valve material into a reaction solution containing an anticoagulant and a cross-linking agent, and performing cross-linking treatment for 6-24 h at 4° C.-37° C.; and finally washing and obtaining the valve material, and storing the valve material in a mixed solvent of glutaraldehyde or isopropyl alcohol/glycerol. The method can effectively solve the problem of calcification and thrombosis caused by residual aldehyde groups in a valve material prepared by the existing method. The valve material prepared by the present method can be used as a valve material required for aortic valve, pulmonary valve, venous valve, mitral valve and tricuspid valve replacement.

A real-tissue surgical training system includes a base and a harvested porcine tissue cassette. A substrate is configured to be removably mounted to the base. Harvested porcine tissue is carried by the substrate and configured to simulate the oropharynx region of the human body and to receive a surgical tool therein for surgical training.